M. Camilleri et al., Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist, ALIM PHARM, 13(9), 1999, pp. 1149-1159
Background: No currently available treatment provides consistent relief of
irritable bowel syndrome, Colonic sensory and motor function are modulated
partly through 5HT(3)-receptors.
Aim: To evaluate effects of the 5HT(3)-receptor antagonist, alosetron, in i
rritable bowel syndrome.
Methods: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2,
4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predo
minant or alternating constipation and diarrhoea irritable bon el syndrome,
Weekly measurement of adequate relief was the key endpoint: other irritabl
e bowel syndrome symptoms were collected daily using an electronic phone sy
stem.
Results: Alosetron (1 mg or 2 mg b.d.) significantly (P < 0.05 vs, placebo)
increased the proportion of females, but not males, reporting adequate rel
ief. Stool consistency, frequency and percentage days with urgency improved
over placebo (P < 0.05) within the first month with all doses of alosetron
, and persisted throughout the trial with all doses in female patients. Wit
h 1 mg b.d. alosetron, females had improved stool consistency and urgency w
ithin the first week, and adequate relief and improved stool frequency with
in the first 2 weeks, There was no consistent improvement in bowel function
among male patients.
Conclusion: In female irritable bowel syndrome patients with predominant di
arrhoea or alternating constipation and diarrhoea, alosetron is effective i
n treatment of abdominal pain and discomfort and bowel-related symptoms.